Protagen is able to measure autoantibodies in autoimmune disease patients to enable the classification of patient subgroups for outlier detection, monitoring of disease activity and response prediction to help develop safer, more effective drugs directed to the right patient.
The incidence of autoimmune diseases is on the rise, resulting in enormous challenges for patients, physicians, payers and the pharma industry alike. This calls for the further development of novel, precision medicine treatments and approaches that will help overcome this global issue.
Autoimmune diseases are generally chronic and progressive—and currently there is no cure for any of them. Their complex pathology, which is characterized by many intricate immune interactions and atypical immune responses, poses a number of challenges, including timely diagnosis, difficulties in predicting therapeutic outcomes and developing novel treatments.
In addition to this, autoimmune diseases are extremely diverse, and the high level of patient heterogeneity observed makes the development of effective treatments challenging. Solving the problem of patient heterogeneity is pivotal for the clinical development of effective and potentially curative treatments.
Luckily, the pathology of autoimmune diseases is underpinned by the presence of autoantibodies, which offers a unique opportunity to address the above challenges. Autoantibodies have been shown to be easily detectable in patient serum, and therefore have become the biomarker of choice for autoimmune diseases.
Despite these advantages and opportunities, autoantibodies have yet to be analyzed systematically in autoimmune diseases, and their potential to define the status of a patient’s immune-competence and responsiveness to treatment remains largely untapped. Protagen’s SeroTag® technology and NavigAID product line does exactly this: and in doing so, supports the development of novel treatments.
The above challenges arise in a number of autoimmune indications despite there currently being numerous treatments available on the market, including the world’s best-selling drug—adalimumab (used to treat rheumatoid arthritis). This calls for the further development of novel, precision medicine treatments and approaches. Diseases such as systemic sclerosis (SSc), systemic lupus erythematosus (SLE), Sjögren’s syndrome (SjS) and rheumatoid arthritis (RA) still have significant, unmet medical needs due to the limited response rates of existing therapies, which is driven by patient heterogeneity—a barrier to successful therapeutic development.
To find out more about how Protagen’s range of precision medicine and patient stratification tools can help meet the above challenges, follow the links below.
Protagen has developed a pipeline of NavigAID stratification arrays, based on autoantibody signatures, for a number of autoimmune diseases to help overcome issues such as patient heterogeneity.
SeroTag® is Protagen’s proprietary biomarker discovery engine, which is used to discover and validate novel biomarkers that can help stratify different cancer indications and autoimmune diseases.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.